ID Connect’s clinical consultant Erin McCreary, PharmD, BCPS, BCIDP, commented on the demise of Evusheld in Time Magazine’s Feb. 8, 2023, online edition. The article, titled “Without Evusheld, Immunocompromised People Are on Their Own Against COVID-19,” explores the effects of the end of the pandemic emergency declarations in May 2023 and the FDA’s revoked emergency-use authorization of Evusheld, a therapy first authorized in Dec. 2021.
You might also like…
Infectious Disease Connect Brings Tele-ID Research and Education to IDWeek 2026
Andrea Carlo Anglero, M.D., Presents at AMPRO 2026 Convention
Putting a Number on the Curbside: ID Connect-Led Study Gets IDSA Spotlight